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a  b  s t  r a  c t
The calculation  of pepitope values,  a sequence-based  measure  of antigenic distance  between  strains,  was
developed  for  human  influenza.  The potential to apply  the  pepitope value  to equine influenza  vaccine strain
selection was assessed.  There  was a negative correlation between pepitope value and vaccine efficacy
for  pairs of vaccine and  challenge  strains  used  in cross-protection  studies  in ponies  that just  reached
statistical  significance  (p =  0.046)  only  if  one  pair  of viruses  was excluded  from the  analysis. Thus the
pepitope value  has potential  to provide additional data  to consider in the  decision-making  process for
updating equine influenza vaccine strains.  However,  further  work  is  required  to define  the  epitopes  of the
equine H3N8  haemagglutinin  protein  recognised  by  equine antibodies, which  could lead  to refinement
of  the  pepitope value calculation.  Furthermore,  other  factors  such  as  vaccine potency  and  virulence  of
circulating  strains  may  also influence  vaccine efficacy.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Equine influenza is a  highly contagious upper respiratory tract
infection caused by influenza virus type A. Vaccines against equine
influenza have been in use since the 1960s; they rely on stimulation
of antibodies to  the surface glycoproteins of the virus, in particular
the haemagglutinin (HA); binding to the HA blocks attachment of
the virus to receptors on host cells. However, continual evolution
of the viral proteins resulting in  changes in the antibody-binding
domains (antigenic sites) diminishes the ability of viruses raised to
an earlier strain to  neutralise a  strain that has undergone ‘anti-
genic drift’ [1].  After major outbreaks caused by H3N8 subtype
equine influenza in  1979–1980, mandatory vaccination of com-
petition horses in  the UK, Ireland and France was introduced,
and A/equine/Fontainebleau/79 (H3N8) or A/equine/Kentucky/81
(H3N8) strains were included in vaccines with the H3N8 prototype
strain A/equine/Miami/63. Having initially evolved in  a  single lin-
eage [2], H3N8 viruses diverged into two lineages (‘Eurasian’ and
‘American’) in the late  1980s [3].  More recently, sub-lineages of the
American lineage have emerged [4] and distinct clades within the
sub-lineages [5].
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A formal vaccine strain selection system for equine influenza
vaccines modelled on the process for human influenza vaccine
strain selection has been in  operation for several years. The cur-
rent recommendation of the OIE Expert Surveillance Panel on
Equine Influenza Vaccine Composition is that equine influenza
vaccines for international use should include two  H3N8 subtype
strains – a  representative of clade 1 of the Florida sub-lineage
(A/equine/South Africa/4/03, A/equine/Ohio/03 or  other similar
strain) and an A/equine/Richmond/1/07-like virus to represent
clade 2 [6].
The decision to  recommend a  vaccine strain update is based pri-
marily on a  combination of antigenic data from haemagglutination
inhibition (HI) assays using ferret antisera and sequencing of the
HA1 portion of the HA, which encodes the major antibody-binding
(antigenic) sites. Additionally, if available, field or  experimental evi-
dence of vaccine breakdown is taken into consideration. Sequence
data offers several potential advantages over antigenic analysis
using ferret antisera, not  least of which is  that it can be rapidly
obtained. Previously, it was  suggested for human influenza that a
minimum of 4 or  5 amino acid changes in at least two  antigenic
sites would indicate a  new antigenic variant [7].  However, studies
have since shown that as few as one or  two amino acid substitut-
ions may  compromise the effectiveness of vaccination sufficiently
for epidemics to occur [8].  Mathematical modelling has suggested
that the same may  be true for equine influenza viruses [9].  However,
there is, to  date, insufficient information to reliably predict indi-
vidual or combinations of amino acid changes that would lead to
vaccine breakdown. Nonetheless, a  sequence-based antigenic dis-
tance measure (the pepitope value) for human influenza A viruses
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Table  1
Vaccine efficacy and pepitope values for pairs of vaccine strains and challenge strains used in experimental cross-protection studies.
Vaccine straina Challenge strain No. ponies SRH antibody (mm2) Vaccine efficacy Pepitope (dominant site) Total amino acid changes
Hom.b Het.c
Miami/63
Sussex/89
10 126 78 10% 0.333 (B) 33
Fontainebleau/79 10 52  18 10% 0.191 (B) 17
Kentucky/81 10 74  40 20% 0.148 (C) 13
Suffolk/89 9 75  46 44% 0.074 (C) 3
Arundel/91
Newmarket/2/93
12  159 120 33% 0.111 (C) 8
Newmarket/1/93 10 167 119 40% 0.191 (B) 12
Newmarket/2/93 Newmarket/1/93 13  132 113 15% 0.191 (B) 12
a GenBank accession numbers: A/equine/Miami/63 (M29257); A/equine/Fontainebleau/79 (CY032405); A/equine/Kentucky/1/81 (CY028820); A/equine/Suffolk/89
(X68437); A/equine/Sussex/89 (X85090); A/equine/Arundel/91 (X85085); A/equine/Newmarket/1/93 (X85088); A/equine/Newmarket/2/93 (X85089).
b Homologous antigen.
c Heterologous antigen.
has been developed for use in  adjunct with other data. Reasonable
correlation between pepitope values and vaccine effectiveness was
demonstrated for human influenza A viruses of the H3N2 subtype
[10–12] and has also been applied to the H1N1 subtype of human
influenza [13].
2. Materials and methods
In order to assess the potential for the sequence-based anti-
genic measure to be applied in  vaccine strain selection for
equine influenza vaccines, the epitope values of various pairs of
equine influenza virus isolates was calculated using the Excel
file made available by  Gupta et al. [11] (http://www.mwdeem.
rice.edu/pepitope). The pepitope value is calculated as the fraction of
substituted amino acids in the dominant HA epitope, thus p-values
are obtained for each of the five antigenic sites of the HA molecule
and the highest value taken as the pepitope value. The antigenic sites
are those identified for the human influenza A H3 HA molecule
[11].  These were used without modification as it has previously
been suggested that the antigenic sites of the equine influenza H3
HA correspond with those of the human influenza H3 HA [14].
The strains analysed were those for which measures of vaccine
efficacy were available from experimental cross-protection stud-
ies in ponies, most of which were vaccine strains or were assessed
as candidate vaccine strains [9,15–17].  Vaccine efficacy was  deter-
mined as the percentage of individuals fully protected from virus
shedding (measured by  titration of nasopharyngeal swab extracts
in embryonated hens’ eggs) after challenge. This is a  more strin-
gent definition of vaccine efficacy than that  used by  Gupta et al.
[11] who used published data from various sources on the effec-
tiveness of human influenza vaccines at preventing influenza-like
illness.
3.  Results and discussion
Overall, the correlation between pepitope value and vaccine effi-
cacy was not significant (linear regression analysis with least
squares estimation, R2 = 0.2317, p =  0.274; Fig. 1). However, there
was a notable discrepancy in  vaccine efficacy for the only virus
pair for which the reciprocal challenge was carried out (Newmar-
ket/1/93 and Newmarket/2/93); the pepitope value for this pair was
0.191 (Table 1). Whereas challenge of Newmarket/2/93-vaccinated
horses with the Newmarket/1/93 strain gave a  vaccine efficacy of
10%, only 4  of 10 ponies vaccinated with the Newmarket/1/93 strain
and challenged with Newmarket/2/93 shed virus, giving a  vaccine
efficacy of 40%. Fontainebleau/79 and Sussex/89 have the same
pepitope value as Newmarket/1/93 and Newmarket/2/93 and the
same immunodominant epitope (site B). Vaccine efficacy for this
pair was  10%, similar to  that for the Newmarket pair when New-
market/1/93 was  the challenge strain, suggesting that the vaccine
efficacy for the Newmarket/2/93 challenge is the outlier.
One potential explanation for an aberrantly high vaccine effi-
cacy is a  markedly more immunogenic vaccine preparation. The
single radial immunodiffusion (SRID) assay is  recommended for
standardisation of the haemagglutinin content of equine influenza
vaccines [18], but homologous standards were not available for
most of the vaccine strains at the time the studies were carried
out. Pre-challenge antibody levels were measured using the sin-
gle radial haemolysis (SRH) assay [18].  Although the mean SRH
values obtained with the heterologous strain were similar for the
Newmarket/1/93 and Newmarket/2/93 vaccine groups, the mean
homologous value was  much higher for the Newmarket/1/93 vac-
cine group (167 mm2 vs 132 mm2).  Furthermore, 7 of the 10 ponies
in the Newmarket/1/93 vaccine group (70%) had homologous pre-
challenge antibody levels of greater than 150 mm2 (the threshold
value previously shown to be  associated with protection against
a heterologous challenge); [19] compared to only 3 of  13 ponies
(23%) in the Newmarket/2/93 vaccine group.
A second potential explanation for the apparently higher effi-
cacy of the Newmarket/1/93 vaccine is  that the challenge was less
rigorous. The Newmarket/2/93 strain was  also used to challenge
Arundel/91-vaccinated ponies; all control ponies shed virus in both
Newmarket/2/93 challenge studies. However, a higher challenge
dose was  used for the Newmarket/2/93 challenge compared to the
Newmarket/1/93 challenge (a total of 109.2 50% egg infectious doses
vs 107.7 EID50) because in preliminary studies, the Newmarket/2/93
strain failed to elicit clinical signs in  some seronegative ponies at
Fig. 1. Correlation between pepitope and vaccine efficacy. The correlation between
pepitope and vaccine efficacy is  shown with (solid line) and without (dotted line) the
data point for Newmarket/1/93 vaccine and Newmarket/2/93 challenge (indicated
by  an  arrow).
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the lower challenge dose [15].  The Newmarket/2/93 strain was also
shown to be a  poorer inducer of pro-inflammatory cytokines than
the Sussex/89 strain [20].  Thus the lower virulence of the New-
market/2/93 strain may  have been a  contributory factor to the
unexpectedly high vaccine efficacy together with the higher anti-
body levels seen in  the Newmarket/1/93-vaccinated ponies. When
the Newmarket/1/93 vaccine and Newmarket/2/93 challenge was
excluded from the data set, the correlation between pepitope and
vaccine efficacy was significant (R2 = 0.6714, p =  0.046) and a pepitope
value >0.2 would appear to be strong indicator that vaccine efficacy
is compromised (i.e. ≤10%).
In conclusion, by excluding one pair of viruses, a  marginally
significant correlation was seen between the proportion of amino
acid changes in the immunodominant epitope and vaccine effi-
cacy for equine influenza A H3N8 strains. In contrast, there was
no significant correlation between total number of amino acid
changes between strains and vaccine efficacy (R2 = 0.6390, p = 0.07).
Although it may  be necessary to take other factors, such as virulence
of a circulating strain, into consideration, further refinement of the
epitope analysis may  be  achieved by mapping the residues of the
equine H3 HA targeted by  neutralising antibodies in  the horse and
assigning greater weight in  the calculation of the pepitope value to
particularly immunodominant residues.
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